Dr. Daniel Morillo Giles

• 2017-actualidad. Médico Adjunto del Servicio de Hematología. Unidad de Linfomas. Hospital Universitario Fundación Jiménez Díaz
• 2017-actualidad. Investigador Clínico. Unidad de Ensayos Clínicos de Fase Temprana START-Madrid FJD (2017-actualidad)
• Médico Adjunto del Servicio de Hematología. Hospital Universitario General de Villalba (2014-2017)
• 2010 – 2014. MIR Hematología y Hemoterapia, Hospital Universitario Puerta de Hierro, Madrid.

Investigación:

• Investigador principal en múltiples ensayos clínicos de fase temprana para Síndromes Linfoproliferativos, Mieloma Múltiple y Leucemia.
• Investigador clínico en proyecto internacional T-cell Project 2.0 (2024)
• Subinvestigador clínico en proyecto: ESTUDIO MOLECULAR INTEGRAL DEL LINFOMA T ANGIOINMUNOBLASTICO, Beca FIS 2021
• Identificación de patrones de metilación de genes supresores tumorales que actúen
• como factores pronósticos o factores de respuesta al tratamiento en el Mieloma Múltiple. Implicaciones de la metilación de dichos genes en la recaída. Beca Asociación Madrileña de Hematología y Hemoterapia, 2016.

Docencia:

• Profesor máster ESAME, Pharmaceutical Business School

Chari A, Touzeau C, Schinke C, Minnema MC, Berdeja JG, Oriol A, van de Donk NWCJ, Rodríguez-Otero P, Morillo D, Martinez-Chamorro C, Mateos MV, Costa LJ, Caers J, Rasche L, Krishnan A, Ye JC, Karlin L, Lipe B, Vishwamitra D, Skerget S, Verona R, Ma X, Qin X, Ludlage H, Campagna M, Masterson T, Hilder B, Tolbert J, Renaud T, Goldberg JD, Kane C, Heuck C, San-Miguel J, Moreau P. Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1-2 study. Lancet Haematol. 2025 Apr;12(4):e269-e281. doi: 10.1016/S2352-3026(24)00385-5. Epub 2025 Mar 13. PMID: 40090350.

Cohen YC, Magen H, Gatt M, Sebag M, Kim K, Min CK, Ocio EM, Yoon SS, Chu MP, Rodríguez-Otero P, Avivi I, Quijano Cardé NA, Kumar A, Krevvata M, Peterson MR, Di Scala L, Scott E, Hilder B, Vanak J, Banerjee A, Oriol A, Morillo D, and Mateos MV; RedirecTT-1 Investigators and Study Group. Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2025 Jan 9;392(2):138-149. doi: 10.1056/NEJMoa2406536. PMID: 39778168.

Díaz de la Pinta FJ, Manso R, Betancor Fernández I, Morillo Giles D, Mollejo M, Rodriguez-Pinilla SM. Association of both BCL2 positive and negative follicular lymphoma to clasical Hodgkin lymphoma and/or gray zone lymphoma. Hum Pathol. 2024 Oct;152:105639. doi: 10.1016/j.humpath.2024.105639. Epub 2024 Aug 14. PMID: 39151736.

Frutos Díaz-Alejo J, Morillo-Giles D, Díaz de la Pinta FJ, Manso R, Rodríguez-Pinilla SM, Rodríguez M. New therapies for angioimmunoblastic T-cell lymphoma: a comprehensive review and analysis. Leuk Lymphoma. 2024 Dec;65(13):2056-2059. doi: 10.1080/10428194.2024.2390567. Epub 2024 Aug 15. PMID: 39148309.

Lopez-Garcia A, Macia E, Gomez-Talavera S, Castillo E, Morillo D, Tuñon J, Ibañez B, Cordoba R. Predictive Factors of Therapy-Related Cardiovascular Events in Patients with Lymphoma Receiving Anthracyclines. Med Sci (Basel). 2024 Apr 24;12(2):23. doi: 10.3390/medsci12020023. PMID: 38804379; PMCID: PMC11130872.

Hormigo-Sanchez AI; Lopez-Garcia A; Mahillo-Fernandez I; Askari E; Morillo D; Perez-Saez MA; Riesco M; Urrutia C; Martinez-Peromingo FJ; Cordoba R; Gonzalez-Montalvo JI. Frailty assessment to individualize treatment in older patients with lymphoma. Eur Geriatr Med. 14 - (6), pp. 1393 - 1402. 12/2023.

Cordoba R; Lopez-Garcia A; Morillo D; Perez-Saenz MA; Askari E; Prieto RE; Castillo Bazan E; Llamas Sillero P; Herrero Gonzalez A; Short Apellaniz J; Del Olmo M; Arcos J. Feasibility of Telemedicine in the Management Strategy of Patients With Lymphoma Amid the COVID-19 Pandemic in Spain: Prospective Observational Study. JMIR Form Res.17 - 7, 17/11/2023.

Haque T; Cadenas FL; Xicoy B; Platzbecker U; Alfonso-Pierola A; Avivi I; Brunner AM; Chromik J; Morillo D; Patel MR; Falantes J; Leitch HA; Germing U; Preis M; Lenox L; Lauring J; Brown RJ; Kalota A; Mehta J; Pastore F; Gu J; Mistry P; Valcárcel D. Phase 1 study of JNJ-64619178, a protein arginine methyltransferase 5 inhibitor, in patients with lower-risk myelodysplastic syndromes. Leukemia Research. 134:107390, 11/2023.

Carlos Santonja; Daniel Morillo-Giles; Elena Prieto-Pareja; Carlos Soto-de Ozaeta; Cristina Serrano-del Castillo; Rocío Salgado-Sánchez; Ana-Wu-Yang Yi-Shi; Rebeca Manso; Socorro María Rodríguez-Pinilla. Leukaemic Presentation of Small-Cell Alk-Positive Anaplastic Large Cell Lymphoma in a Young Woman-Report of a Case with 9-Year Survival. Medicina. 59(9), pp. 1628. 08/09/2023.

Morillo D; Vega V; Moreno V. CDK9 INHIBITORS: a promising combination partner in the treatment of hematological malignancies. Oncotarget. 14, pp. 749 - 752. 07/08/2023.

Tahir SK, Calvo E, Carneiro BA, Yuda J, Shreenivas A, Jongen-Lavrencic M, Gort E, Ishizawa K, Morillo D, Biesdorf C, Smith M, Cheng D, Motwani M, Sharon D, Uziel T, Modi DA, Buchanan FG, Morgan-Lappe S, Medeiros BC, Phillips DC. Activity of eftozanermin alfa plus venetoclax in preclinical models and patients with acute myeloid leukemia. Blood. 2023 Apr 27;141(17):2114-2126. doi: 10.1182/blood.2022017333. PMID: 36720090; PMCID: PMC10646782.

Haque T, Cadenas FL, Xicoy B, Alfonso-Pierola A, Platzbecker U, Avivi I, Brunner AM, Chromik J, Morillo D, Patel MR, Falantes J, Leitch HA, Germing U, Preis M, Lenox L, Lauring J, Brown RJ, Kalota A, Mehta J, Pastore F, Gu J, Mistry P, Valcárcel D. Phase 1 study of JNJ-64619178, a protein arginine methyltransferase 5 inhibitor, in patients with lower-risk myelodysplastic syndromes. Leuk Res. 2023 Nov;134:107390. doi: 10.1016/j.leukres.2023.107390. Epub 2023 Sep 20. PMID: 37776843.

Diamond JR; Boni V; Valencia R; Nowakowski G; Cordoba R; Morillo D; Genvresse I; Merz C; Boix O; Lim E; Moreno V. First-in-Human Dose-Escalation Study of Cyclin-Dependent Kinase 9 Inhibitor VIP152 in Patients with Advanced Malignancies Shows Early Signs of Clinical Efficacy. Clin Cancer Res. 28 - 7, pp. 1285 - 1293. 11/04/2022

Rodríguez-Pinilla SM; Salgado RN; Chamizo C; Santonja C; Stewart P; Carvajal N; McCafferty N; Manso R; Morillo D; Piris MÁ; González de Castro D. Redefining the high-grade B cell lymphoma with double/triple rearrangements of MYC and BCL2/BCL6 genes. Learning from a case report.European Journal of Haematology. 3 - (1), pp. 171 -174. 09/11/2021.

Stefania Infante M; Fernández-Cruz A; Núñez L; Carpio C; Jiménez-Ubieto A; López-Jiménez J; Vásquez L; Del Campo R; Romero S; Alonso C; Morillo D; Prat M; Luis Plana J; Villafuerte P; Bastidas G; Bocanegra A; Serna Á; De Nicolás R; Marquet J; Mas-Ochoa C; Cordoba R; García-Suárez J; Comai A; Martín X; Bastos-Oreiro M; Seri C; Navarro-Matilla B; López-Guillermo A; Martínez-López J; Ángel Hernández-Rivas J; Ruiz-Camps I; Grande C. Severe infections in patients with lymphoproliferative diseases treated with new targeted drugs: A multicentric real-world study. Cancer Medicine. 10 - (21), pp. 7629 - 7640. 11/2021.

Alonso-Alonso R; Rodriguez M; Morillo D; Cordoba R; Piris MA. An analysis of genetic targets for guiding clinical management of follicular lymphoma. Expert Rev Hematol. 13 - 12, pp. 1361 - 1372. 13/12/2020.

Miembro de la Sociedad Española de Hematología y Hemoterapia, Grupo Español de Linfomas y Asociación Madrileña de Hematología y Hemoterapia